Immunovia's CLARITI study results selected for prestigious presentation at the world's largest gastroenterology conference
Rhea-AI Summary
Immunovia (IMMNOV: Nasdaq Stockholm) announces that its CLARITI study results have been selected for a distinguished plenary presentation at the Digestive Disease Week® (DDW) 2025 conference on May 5, 2025. The study was chosen as one of only six abstracts for the AGA Institute Council's Pancreatic Disorders Section Distinguished Abstract Plenary.
Dr. Aimee Lee Lucas, Chief of Gastroenterology at Mount Sinai West and Mount Sinai Morningside Hospitals, will present findings on the clinical validation of Immunovia's novel blood-based multi-biomarker test for early pancreatic ductal adenocarcinoma (PDAC) detection in high-risk populations. As a member of Immunovia's Scientific Advisory Board, Dr. Lucas contributed to the study's design and sample collection.
Positive
- Study selected as 1 of only 6 abstracts for prestigious plenary presentation
- Strong performance of next-generation pancreatic cancer detection test validated
- Recognition validates scientific quality and addresses unmet clinical need
Negative
- None.
The CLARITI study was selected as one of only six abstracts to be presented at the AGA Institute Council's Pancreatic Disorders Section Distinguished Abstract Plenary—an honor reserved for research demonstrating exceptional scientific and clinical impact.
Dr. Aimee Lee Lucas, Chief of Gastroenterology and Hepatology at Mount Sinai West and Mount Sinai Morningside Hospitals and Professor of Medicine at Icahn School of Medicine, will present the CLARITI study findings at DDW 2025. Her presentation, titled "Clinical validation of a novel blood-based multi-biomarker test for the early detection of pancreatic ductal adenocarcinoma (PDAC) in an independent high-risk population shows similar high performance as observed in its model development study," highlights the study's robust methodology and the strong performance of Immunovia's next-generation test.
As a member of the Immunovia Scientific Advisory Board, Dr. Lucas was integral to the study's design and played a key role in the collection of blood samples.
"I am excited to present these data at the world's largest conference for gastroenterologists. Selection of these study results for a distinguished plenary oral presentation underscores the rigor of the CLARITI validation study and the strong performance of the Immunovia test in the study," says Dr. Aimee Lee Lucas.
"We are very proud to see the CLARITI study receive this remarkable recognition. It's a strong statement about the quality of our science and it highlights the importance of the unmet clinical need our new test addresses," says Jeff Borcherding, Immunovia CEO.
About Digestive Disease Week
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and other professional societies, DDW is an in-person and online meeting from May 3-6, 2025. The meeting is expected to include more than 13,000 attendees encompassing global researchers, clinicians and key decision-makers in gastroenterology and hepatology.
For further information, please contact
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com
Karin Almqvist Liwendahl, CFO
karin.almqvist.liwendahl@immunovia.com
+46 70 911 56 08
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovias-clariti-study-results-selected-for-prestigious-presentation-at-the-worlds-largest-gastroenterology-conference-302389808.html
SOURCE Immunovia AB
FAQ
What is the significance of IMMNOV's CLARITI study being selected for DDW 2025?
What is the focus of Immunovia's (IMMNOV) CLARITI study presentation at DDW 2025?
When and where will IMMNOV's CLARITI study results be presented?
Who will present Immunovia's (IMMNOV) CLARITI study at DDW 2025?
